WeightWatchers is betting on women’s health.
The latest: Fresh out of bankruptcy, WeightWatchers is relisting on NASDAQ and repositioning as a women’s health company.
As part of its restructuring, WW named industry veteran Dr. Kim Boyd as chief medical officer, appointed a new board (including Eli Lilly’s former obesity chief), and announced a clinical program to support women through perimenopause, menopause, and beyond.
New playbook. The weight loss brand struggled to keep pace with GLP-1s, despite acquiring telehealth startup Sequence in 2023.Retooling, WW now plans to help women manage metabolic and life stage shifts with a mix of functional and clinical care, combining nutrition, coaching, community, and hormone therapies.
Still a primary driver, it’ll continue to prescribe weight loss meds, partneringwith Novo Nordisk following the drugmaker’s fallout with Hims & Hers.
White space. While 70% of women experience weight gain during menopause, few trusted brands offer integrated support.
As GLP-1s gain acceptance, WW is the latest entrant reframing weight loss as speciality whole-person care. Branching out, menopause care platform Midi Health added $60M and entered female-focused longevity, while Hims & Hers and Noom layer in HRT.
Punchline: WeightWatchers missed the GLP-1 boom. Trying to catch the next wave, it’s attempting to meet women where they are with hormone-aware, longevity-focused care.
